CDK6 and neutropenia: We investigated how CDK6 inhibition with indole-3-carbinol (I3C) or systemic Cdk6-deficiency in a murine model of arthritis ameliorates the progression of pathological changes and suppresses synovial hyperplasia without affecting myelosuppression, particularly neutropenia.